Grufity logoGrufity logo
StocksFundsSearch Filings

Glaukos Corp Stock Research

GKOS

54.85USD-0.38(-0.69%)Market Closed

Market Summary

USD54.85-0.38
Market Closed
-0.69%

GKOS Alerts

GKOS Stock Price

GKOS RSI Chart

GKOS Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-18.89

Price/Sales (Trailing)

9.1

EV/EBITDA

-21.71

Price/Free Cashflow

-25.24

GKOS Price/Sales (Trailing)

GKOS Profitability

EBT Margin

-34.80%

Return on Equity

-18.72%

Return on Assets

-9.9%

Free Cashflow Yield

-3.96%

GKOS Fundamentals

GKOS Revenue

Revenue (TTM)

289.1M

Revenue Y/Y

9.19%

Revenue Q/Q

3.75%

GKOS Earnings

Earnings (TTM)

-139.2M

Earnings Y/Y

-743.97%

Earnings Q/Q

-10.06%

Price Action

52 Week Range

39.5161.01
(Low)(High)

Last 7 days

-6.5%

Last 30 days

17.0%

Last 90 days

15.2%

Trailing 12 Months

34.9%

GKOS Financial Health

Current Ratio

6.13

GKOS Investor Care

Shares Dilution (1Y)

1.81%

Diluted EPS (TTM)

-2.92

Peers (Alternatives to Glaukos)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
110.8B
19.0B
-8.78% 16.43%
46.98
6.01
8.73% 30.37%
107.5B
6.4B
4.05% 37.44%
81.96
16.72
8.89% -20.19%
74.1B
13.0B
-0.08% 27.20%
106.12
5.84
7.26% -32.95%
71.3B
18.8B
-6.73% -3.13%
44.09
3.79
-1.96% -15.83%
49.7B
5.5B
-6.18% -16.80%
33.38
9.03
2.68% -3.23%
MID-CAP
7.2T
557.2M
-1.64% 66.40%
82.2K
16.8K
86.42% 730.06%
11.7B
884.6M
7.85% 115.97%
1.8K
13.2
13.08% 200.12%
5.9B
1.1B
-8.20% -19.98%
34.14
5.75
11.20% 53.04%
3.6B
430.0M
-11.89% -12.63%
-34.73
8.45
26.13% 15.73%
1.7B
794.7M
-29.15% -60.56%
-8.43
2.16
7.73% -3556.34%
SMALL-CAP
1.6B
389.0M
-3.76% 82.19%
-10.63
4.18
44.08% 6.96%
1.2B
150.7M
-30.80% 0.49%
-21.65
7.87
40.31% 1.80%
1.1B
814.3M
-20.14% -16.22%
24.47
1.34
6.96% 121.89%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%

Financials for Glaukos

Income Statement (Last 12 Months)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue2.2%289,080,000282,862,000284,875,000288,316,000293,724,000
Gross Profit2.4%219,093,000213,883,000216,253,000221,185,000226,667,000
Operating Expenses16.2%344,191,000296,196,000282,701,000254,998,000237,942,000
  S&GA Expenses5.0%202,626,000192,925,000188,564,000185,885,000181,285,000
  R&D Expenses-107,508,000----
EBITDA-11.8%-78,045,000-69,783,000-11,682,00015,963,000-
EBITDA Margin-12.6%-0.28-0.24-0.040.05-
Earnings Before Taxes-40.6%-138,357,000-98,429,000-89,502,000-55,741,000-27,374,000
EBT Margin-10.8%-0.35-0.31-0.19-0.09-
Interest Expenses-0.1%13,712,00013,720,00013,735,00013,667,00013,559,000
Net Income-40.3%-139,198,000-99,195,000-89,607,000-55,801,000-27,747,000
Net Income Margin-11.5%-0.35-0.31-0.19-0.09-
Free Cahsflow2.5%-63,348,000-64,969,000-24,541,000-6,911,000-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-3.0%9731,0021,0081,0311,052
  Current Assets-6.3%416444449471491
    Cash Equivalents-30.2%83.00120104103106
  Inventory6.9%40.0038.0034.0028.0025.00
  Net PPE4.2%98.0094.0087.0081.0075.00
  Goodwill0%66.0066.0066.0066.0066.00
Liabilities-1.8%464472460469455
  Current Liabilities-13.8%62.0072.0061.0070.0056.00
Shareholder's Equity-4.1%509530549562598
  Retained Earnings-7.5%-499-464-432-405-359
  Additional Paid-In Capital1.2%1,009997985972961
Shares Outstanding0.4%48.0048.0048.0047.0047.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-122.5%-73.62-33.08-33.6011.0030.00
  Share Based Compensation8.5%42.0039.0034.0031.0028.00
Cashflow From Investing-17.7%37.0045.0019.00-31.20-42.87
Cashflow From Financing-4.1%6.006.007.007.0023.00

Risks for GKOS

What is the probability of a big loss on GKOS?

97.3%


Probability that Glaukos stock will be more than 20% underwater in next one year

65%


Probability that Glaukos stock will be more than 30% underwater in next one year.

40.4%


Probability that Glaukos stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does GKOS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Glaukos was unfortunately bought at previous high price.

Drawdowns

Returns for GKOS

Cumulative Returns on GKOS

12.3%


7-Year Cumulative Returns

8.4%


5-Year Cumulative Returns

11.9%


3-Year Cumulative Returns

What are the long-term rolling returns for GKOS?

FIve years rolling returns for Glaukos.

Annualized Returns

Which funds bought or sold GKOS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-3.36
873,582
8,933,580
-%
2023-05-22
PUTNAM INVESTMENTS LLC
reduced
-4.00
48,991
533,665
-%
2023-05-19
Coppell Advisory Solutions LLC
sold off
-100
-407
-
-%
2023-05-18
JPMORGAN CHASE & CO
reduced
-41.09
-2,258,000
4,707,000
-%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
19.64
6,929,000
25,545,000
0.03%
2023-05-17
Thrivent Financial for Lutherans
reduced
-3.39
231,000
2,368,000
0.01%
2023-05-17
VIRGINIA RETIREMENT SYSTEMS ET AL
sold off
-100
-298,144
-
-%
2023-05-16
Rockefeller Capital Management L.P.
sold off
-100
-
-
-%
2023-05-16
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC
unchanged
-
250,997
1,958,710
0.05%
2023-05-16
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
30.77
1,506,690
4,520,820
-%

1–10 of 41

Latest Funds Activity

Are funds buying GKOS calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own GKOS
No. of Funds

Glaukos News

MarketBeat
Glaukos Co. (NYSE:GKOS) Shares Sold by Aigen Investment ....
MarketBeat,
25 hours ago
Stockhouse Publishing
InvestorsObserver
InvestorsObserver
InvestorsObserver
Orange County Business Journal
Larger Health Firms Report Mixed Q1 Results.
Orange County Business Journal,
12 days ago
InvestorsObserver
Investor's Business Daily

Schedule 13G FIlings of Glaukos

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
brown capital management llc
5.69%
2,712,809
SC 13G/A
Feb 14, 2023
burns thomas william
5.71%
2,807,641
SC 13G/A
Feb 09, 2023
vanguard group inc
11.21%
5,349,225
SC 13G/A
Feb 06, 2023
wellington management group llp
9.19%
4,385,656
SC 13G/A
Jan 31, 2023
blackrock inc.
16.3%
7,783,794
SC 13G
Feb 14, 2022
burns thomas william
5.65%
2,725,557
SC 13G/A
Feb 14, 2022
brown capital management llc
6.44%
3,021,796
SC 13G/A
Feb 04, 2022
artisan partners limited partnership
4.2%
1,983,513
SC 13G/A
Jan 28, 2022
blackrock inc.
15.8%
7,423,702
SC 13G/A
Jan 10, 2022
wellington management group llp
10.50%
4,923,297
SC 13G

GKOS Fair Value

Recent SEC filings of Glaukos

View All Filings
Date Filed Form Type Document
May 23, 2023
144
Notice of Insider Sale Intent
May 23, 2023
4
Insider Trading
May 19, 2023
144
Notice of Insider Sale Intent
May 19, 2023
4
Insider Trading
May 18, 2023
144
Notice of Insider Sale Intent
May 17, 2023
144
Notice of Insider Sale Intent
May 17, 2023
4
Insider Trading
May 17, 2023
8-K
Current Report
May 16, 2023
144
Notice of Insider Sale Intent
May 15, 2023
144
Notice of Insider Sale Intent

Latest Insider Trading transactions for GKOS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-23
Burns Thomas William
acquired
50.925
7.275
7.00
chairman & ceo
2023-05-23
Burns Thomas William
sold
-420
60.00
-7.00
chairman & ceo
2023-05-19
Burns Thomas William
sold
-60.21
60.21
-1.00
chairman & ceo
2023-05-19
Burns Thomas William
acquired
7.275
7.275
1.00
chairman & ceo
2023-05-18
Burns Thomas William
acquired
84,841
7.275
11,662
chairman & ceo
2023-05-18
Burns Thomas William
sold
-701,749
60.174
-11,662
chairman & ceo
2023-05-17
Burns Thomas William
acquired
4,510
7.275
620
chairman & ceo
2023-05-17
Burns Thomas William
sold
-37,223
60.038
-620
chairman & ceo
2023-05-16
Burns Thomas William
acquired
26,946
7.275
3,704
chairman & ceo
2023-05-16
Burns Thomas William
sold
-222,273
60.009
-3,704
chairman & ceo

1–10 of 50

Thomas W. Burns
730
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

GKOS Income Statement

2023-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
Net sales$ 73,899$ 67,681
Cost of sales18,07117,063
Gross profit55,82850,618
Operating expenses:  
Selling, general and administrative53,65043,949
Research and development35,17126,877
Litigation-related settlement (30,000)
Total operating expenses88,82140,826
(Loss) income from operations(32,993)9,792
Non-operating expense:  
Interest income1,648287
Interest expense(3,408)(3,416)
Other income (expense), net528(960)
Total non-operating expense(1,232)(4,089)
(Loss) income before taxes(34,225)5,703
Income tax provision401326
Net (loss) income$ (34,626)$ 5,377
Basic net (loss) income per share (in dollar per share)$ (0.72)$ 0.11
Diluted net (loss) income per share (in dollar per share)$ (0.72)$ 0.11
Weighted average shares used to compute basic net (loss) income per share47,88147,050
Weighted average shares used to compute diluted net (loss) income per share47,88149,506

GKOS Balance Sheet

2023-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 76,398$ 119,525
Short-term investments241,371233,170
Accounts receivable, net37,85236,073
Inventory40,45537,841
Prepaid expenses and other current assets19,80417,250
Total current assets415,880443,859
Restricted cash7,0787,078
Property and equipment, net98,33194,403
Operating lease right-of-use assets26,64025,826
Finance lease right-of-use asset45,99646,601
Intangible assets, net301,640307,869
Goodwill66,13466,134
Deposits and other assets10,89310,613
Total assets972,5921,002,383
Current liabilities:  
Accounts payable12,02914,403
Accrued liabilities50,36357,956
Total current liabilities62,39272,359
Convertible senior notes281,743281,400
Operating lease liability29,47528,905
Finance lease liability72,02372,172
Deferred tax liability, net7,2597,264
Other liabilities11,18610,278
Total liabilities464,078472,378
Commitments and contingencies (Note 12)
Stockholders' equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 150,000 shares authorized; 47,969 and 47,782 shares issued and 47,941 and 47,754 shares outstanding as of March 31, 2023 and December 31, 2022, respectively4848
Additional paid-in capital1,008,955997,470
Accumulated other comprehensive loss(1,325)(2,975)
Accumulated deficit(499,032)(464,406)
Less treasury stock (28 shares as of March 31, 2023 and December 31, 2022)(132)(132)
Total stockholders' equity508,514530,005
Total liabilities and stockholders' equity$ 972,592$ 1,002,383